ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2670

Giant Cell Arteritis with Intracranial Vasculitis: A Case Series

Catalina Sanchez-Alvarez1, Alexander Hawkins 1, Matthew Koster 2, Vance T. Lehman 3, Cynthia Crowson 1 and Kenneth Warrington 2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Rochester, Rochester, MN, 3Mayo Clinic, Rochester

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis, large vessel vasculitis and CNS Vasculitis, Temporal arteritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that primarily affects the aorta and its branches. Extracranial branches of the carotid artery are frequently affected; however, intracranial involvement in GCA is rare.

To determine the clinical features and outcome of patients with intracranial giant cell arteritis (IC-GCA).

Methods: A retrospective medical record review was performed to identify all patients with IC-GCA from 1/1996 through 5/2018. Demographic, clinical, laboratory, radiographic, and treatment data at baseline and subsequent follow-up visits were collected. Data was summarized using descriptive statistics

Results: The study cohort included 9 patients with IC-GCA (78% male, mean [±SD] age 72.1 [±7.9] years). 8 of 9 patients had positive temporal artery biopsies. One patient with negative biopsy had evidence of large-vessel GCA on thoracic CT angiography. The mean time from onset of GCA to intracranial involvement was 17 months (±38). All patients had neurologic symptoms, 33% (n:3) had a stroke and 22% (n:2) had a transient ischemic attack. IC-GCA was diagnosed by cranial imaging in 8 patients and by autopsy in one. Cranial imaging modalities used included magnetic resonance angiography (n=8), CT angiography (n=2) and cerebral angiography (n=2). Intracranial vasculitis most commonly affected the internal carotid artery 78% (N=7) followed by the, vertebral artery 56% (n=5), posterior cerebral artery 56% (n=5), middle cerebral artery 44% (n=4), anterior cerebral artery 33% (n=3) and posterior inferior cerebral artery 11% (n=1). Stenosis was present in 89%, occlusion in 33%, dilatation in 11%, and wall thickening in 11%. All patients received glucocorticoids. For treatment of intracranial disease additional agents included: cyclophosphamide (67%), Tocilizumab (22 %). Despite treatment, outcomes for patients with IC-GCA were poor. Five of nine patients died during a mean length of follow-up of 2.4 months. Comparing IC-GCA patient survival to the expected rates from the U.S. population (Figure 1), the standardized mortality ratio (95% CI) for IC-GCA was 179.7 (58.3, 419.4); p< 0.001.

Conclusion: Although rare, IC-GCA is associated with significant morbidity and mortality. It occurs predominantly in men, presenting with ischemic cerebrovascular events. Current treatment strategies appear to be of limited efficacy for IC-GCA.


IC-GCA table


Disclosure: C. Sanchez-Alvarez, None; A. Hawkins, None; M. Koster, None; V. Lehman, None; C. Crowson, None; K. Warrington, Eli Lilly, 2, GlaxoSmithKline, 2, roche, 2, 8, Roche, 2, 5, 8, Sanofi, 5, sanofi, 5.

To cite this abstract in AMA style:

Sanchez-Alvarez C, Hawkins A, Koster M, Lehman V, Crowson C, Warrington K. Giant Cell Arteritis with Intracranial Vasculitis: A Case Series [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/giant-cell-arteritis-with-intracranial-vasculitis-a-case-series/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/giant-cell-arteritis-with-intracranial-vasculitis-a-case-series/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology